Premium
In vivo preservation of steroid specificity in CWR22 xenografts having a mutated androgen receptor
Author(s) -
Shao Tsang C.,
Li Huiling,
Eid Wael,
Ittmann Michael,
Unni Emmanual,
Cunningham Glenn R.
Publication year - 2003
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.10266
Subject(s) - flutamide , androgen receptor , in vivo , endocrinology , medicine , testosterone (patch) , androgen , prostate cancer , prostate , steroid , syngenic , dihydrotestosterone , receptor , biology , cancer , hormone , transplantation , microbiology and biotechnology
Background In vitro studies of CWR22 tumor cells lack steroid specificity. We sought to determine if CWR22 xenografts also lack steroid specificity. Methods We injected castrated nude mice with CWR22 tumor cells (6 × 10 6 cells) and implanted Alzet osmotic pumps that delivered approximately 1 mg steroid/kg body weight/day. Results Serum PSA levels were detectable in intact mice and castrated mice treated with testosterone (T), but not in those treated with estradiol (E 2 ), progesterone (P), or flutamide (F). T maintained mean tumor weight similar to that in intact mice ( P = NS). We observed no tumors in castrated mice or mice treated with E 2 , P, or F, and tumor histology was consistent with weights. Conclusions The mutation of the androgen receptor (H874Y) that occurs in the CWR22 xenograft model of human prostate cancer does not significantly affect in vivo steroid specificity for E 2 , P, or F. Prostate 57: 1–7, 2003. © 2003 Wiley‐Liss, Inc.